A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Description

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.

Conditions

Hidradenitis Suppurativa

Talk to us

Study Overview

On this page

Study Details

Study overview

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.

A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Condition
Hidradenitis Suppurativa
Intervention / Treatment

-

Contacts and Locations

Phoenix

Medical Dermatology Specialists, Phoenix, Arizona, United States, 85006

Phoenix

Saguaro Dermatology Associates, LLC - Probity - PPDS, Phoenix, Arizona, United States, 85008

North Little Rock

Arkansas Research Trials, LLC, North Little Rock, Arkansas, United States, 72117

Rogers

Northwest Arkansas Clinical Trials Center, Rogers, Arkansas, United States, 72758

Fountain Valley

First OC Dermatology Research Inc, Fountain Valley, California, United States, 92708

Fremont

Center for Dermatology Clinical Research, Inc., Fremont, California, United States, 94538

Los Angeles

Dermatology Research Associates, Los Angeles, California, United States, 90045

Santa Monica

Dermatology Institute and Skin Care Center, Santa Monica, California, United States, 90404

Farmington

University of Connecticut, Farmington, Connecticut, United States, 06032

Hialeah

Direct Helpers Research Center, Hialeah, Florida, United States, 33012

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Have a diagnosis of HS for at least 12 months.
  • * Have HS lesions in at least 2 distinct anatomical regions. At least 1 of the lesions must be at least Hurley Stage II or III.
  • * Have an (abscess plus inflammatory nodule) count of at least 5.
  • * Agree to use topical antiseptics daily.
  • * Had an inadequate response or intolerance to a 28-day course of oral antibiotics.
  • * Have more than 20 draining fistulae.
  • * Have had surgical treatment for HS in the last 4 weeks before randomization.
  • * Have an active skin disease or condition, that could interfere with the assessment of HS.
  • * Have a current or recent acute, active infection.
  • * Are immunocompromised.
  • * Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year before screening.

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Eli Lilly and Company,

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company

Study Record Dates

2026-07